6 Since then, states have altered their positions on covering anti-obesity GLP-1 therapies: Four have withdrawn coverage entirely (California, New Hampshire, Pennsylvania, and South Carolina), three have added coverage (Missouri, Tennessee, and Utah), and at least two states (Michigan and Virginia) have enacted more narrow utilization criteria, limiting future use to those with morbid obesity
doi: 10.1038/labinvest.2016.76 134 BeachTAGrovesAMWilliamsJPFinkelsteinJN
Tirzepatide produces substantial weight loss, 7-13 kg in clinical trials, through potent appetite suppression, delayed gastric emptying, and direct effects on fat metabolism through GIP receptor activation
These photos help set realistic expectations and provide a clearer understanding of how subtle, gradual fat reduction can significantly enhance both facial contours and overall body shape over time
These investigations support a deeper understanding of the biochemical substrates of cognition and facilitate the identification of novel targets for modulating neural circuit function
